NASDAQ
507.56USD
+0.19 (+0.04%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
11.7B
P/E
—
EPS
—
Beta
-1.00
52W range
351.32-615
Day range
494.90–509.87
Open
502.11
Prev close
507.37
Volume
229.5K
Avg volume
338.1K
Dividend
0.00
IPO
2007-02-06
https://www.marketbeat.com/instant-alerts/madrigals-rezdiffra-hits-13b-run-rate-as-mash-pipeline-expands-2026-08-15/ · 8/15/2026+1.00
https://www.prnewswire.com/news-releases/ribo-and-madrigal-reach-first-major-milestone-in-advancing-novel-sirna-therapies-for-mash-302816515.html · 7/2/2026+1.00
https://247wallst.com/investing/2026/06/20/wall-street-technician-declares-financials-industrials-and-biotech-poised-for-breakouts-3-etfs-could-soar/ · 6/20/2026+0.40
https://seekingalpha.com/article/4911222-madrigal-pharmaceuticals-could-become-the-next-vertex · 6/3/2026+0.60
https://247wallst.com/investing/2026/05/03/3-biotech-stocks-to-watch-for-respectable-growth-beyond-ai/ · 5/3/2026+0.80
https://www.fool.com/coverage/filings/2026/03/21/this-new-usd193-million-bet-targets-a-biotech-with-usd689-million-in-revenue-and-a-potential-turnaround-story/ · 3/21/2026+0.00
https://www.fool.com/coverage/filings/2026/03/21/this-usd116-million-buy-joins-a-360-stock-run-and-seemingly-signals-conviction-in-a-key-drug-launch/ · 3/21/2026+0.30
https://www.defenseworld.net/2026/02/28/artisan-partners-limited-partnership-acquires-4683-shares-of-madrigal-pharmaceuticals-inc-mdgl.html · 2/28/2026+0.20
https://www.zacks.com/stock/news/2872923/madrigal-q4-earnings-miss-mash-drug-sales-drive-top-line-stock-down?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2872923 · 2/20/2026-0.40
https://www.zacks.com/stock/news/2862358/madrigal-mdgl-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_9-2862358 · 2/12/2026+0.60
https://247wallst.com/investing/2026/01/31/insiders-are-still-scooping-up-under-armour-and-wr-berkley-shares/ · 1/31/2026+0.10
https://www.globenewswire.com/news-release/2026/01/09/3216039/0/en/Madrigal-Expands-its-MASH-Pipeline-with-Exclusive-Global-License-Agreement-for-Ervogastat-a-Phase-2-Oral-DGAT-2-Inhibitor.html · 1/9/2026+0.80
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
